Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Codiak Biosciences Inc (CDAK)

Codiak Biosciences Inc (CDAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 403,074
  • Shares Outstanding, K 22,331
  • Annual Sales, $ 2,920 K
  • Annual Income, $ -91,670 K
  • 60-Month Beta N/A
  • Price/Sales 144.71
  • Price/Cash Flow N/A
  • Price/Book 7.18
Trade CDAK with:

Options Overview Details

View History
  • Implied Volatility 105.25%
  • Historical Volatility 43.94%
  • IV Percentile 28%
  • IV Rank 28.36%
  • IV High 124.26% on 09/14/21
  • IV Low 97.73% on 08/18/21
  • Put/Call Vol Ratio 0.71
  • Today's Volume 29
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 4.50
  • Today's Open Interest 22
  • Open Int (30-Day) 8

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.94
  • Number of Estimates 2
  • High Estimate -0.90
  • Low Estimate -0.99
  • Prior Year -12.83
  • Growth Rate Est. (year over year) +92.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.22 +16.21%
on 09/13/21
19.99 -5.70%
on 09/17/21
+1.06 (+5.96%)
since 08/23/21
3-Month
15.25 +23.61%
on 07/15/21
22.95 -17.86%
on 08/09/21
-1.21 (-6.03%)
since 06/23/21

Most Recent Stories

More News
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has...

CDAK : 18.85 (+4.43%)
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.85 (+4.43%)
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.85 (+4.43%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 15.02 (+4.74%)
SANA : 23.01 (+2.82%)
SGTX : 5.80 (+7.01%)
AXLA : 3.07 (unch)
CDAK : 18.85 (+4.43%)
EVLO : 7.47 (+1.08%)
KLDO : 5.66 (-0.53%)
MRNA : 454.60 (+3.15%)
RUBY : 19.30 (-0.05%)
MCRB : 7.09 (+1.00%)
Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.85 (+4.43%)
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.07 (unch)
CDAK : 18.85 (+4.43%)
DNLI : 52.90 (+1.77%)
EVLO : 7.47 (+1.08%)
FHTX : 15.02 (+4.74%)
KLDO : 5.66 (-0.53%)
MCRB : 7.09 (+1.00%)
MRNA : 454.60 (+3.15%)
RUBY : 19.30 (-0.05%)
SANA : 23.01 (+2.82%)
SGTX : 5.80 (+7.01%)
Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has...

CDAK : 18.85 (+4.43%)
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.07 (unch)
CDAK : 18.85 (+4.43%)
DNLI : 52.90 (+1.77%)
EVLO : 7.47 (+1.08%)
FHTX : 15.02 (+4.74%)
KLDO : 5.66 (-0.53%)
MCRB : 7.09 (+1.00%)
MRNA : 454.60 (+3.15%)
RUBY : 19.30 (-0.05%)
SANA : 23.01 (+2.82%)
SGTX : 5.80 (+7.01%)
New Preclinical Data Demonstrate Potential of Codiak's Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new...

CDAK : 18.85 (+4.43%)
Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.85 (+4.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 20.94
2nd Resistance Point 20.14
1st Resistance Point 19.49
Last Price 18.85
1st Support Level 18.05
2nd Support Level 17.25
3rd Support Level 16.60

See More

52-Week High 37.85
Fibonacci 61.8% 26.41
Fibonacci 50% 22.88
Fibonacci 38.2% 19.34
Last Price 18.85
52-Week Low 7.90

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar